Mapping the high throughput SEREX technology screening for novel tumor antigens

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Novel tumor-associated antigen (TAA) screening strategies are crucial for advancing cancer subtyping, diagnosis, and therapeutics.
• Identifying TAAs facilitates early cancer detection and enhances treatment efficacy.
• Current non-invasive methods focus on discovering human tumor antigens recognized by autologous antibodies or T lymphocytes.

Purpose of the Study:

• To review the Serological Analysis of Recombinant cDNA Expression Libraries (SEREX) technology for identifying tumor antigens.
• To outline the advantages, drawbacks, and modifications of SEREX.
• To translate SEREX-defined peptides into cancer-specific signatures for diagnostics and therapeutics.

Main Methods:

• SEREX involves immunoscreening cDNA libraries from tumor tissues with patient sera to detect IgG antibody-recognized gene products.
• SEREX technology offers high sensitivity and broad antigen coverage.
• SEREX-defined clones allow for direct sequencing and expression profiling for structural definition of antigenic targets.

Main Results:

• SEREX is the first established technology for discovering tumor antigens with outstanding sensitivity and coverage.
• SEREX enables the identification of TAAs and their corresponding autoantibodies.
• SEREX-defined peptides can be translated into cancer-specific signatures.

Conclusions:

• SEREX technology is a valuable tool for discovering novel tumor antigens and autoantibodies.
• SEREX-identified biomarkers can aid in the development of cancer diagnostics, prognostics, and therapeutics.
• Advances in TAA screening, including SEREX, enhance cancer detection and treatment approaches.